Endo International confirms subsidiary receives grand jury subpoena from US Attorney's Office of Southern District of Florida

In a statement, the company said the subpoena is seeking information relating to products containing the opioid oxymorphone
Drugs
Endo International said it intends to cooperate with the subpoena and any related investigation

Endo International PLC (NASDAQ:ENDP) saw its shares shed 3% in pre-market trading after the company confirmed that its subsidiary, Endo Pharmaceuticals Inc., has received a grand jury subpoena from the US Attorney's Office for the Southern District of Florida.

In a statement, the company said the subpoena is seeking information relating to products containing the opioid oxymorphone.

It said it also is seeking documents including those produced in past or pending lawsuits, as well as those relating to safety and efficacy, overdoses, abuse/misuse and overprescribing, among other issues.

The group said it intends to cooperate with the subpoena and any related investigation.

In pre-market trading in New York, Endo International shares were down 3% at US$7.83.

View full ENDP profile View Profile

Endo Pharmaceuticals Timeline

Newswire
November 24 2014

Related Articles

woman at a microscope
September 04 2017
Lead product Lojuxta generated revenues of €5.75mln in the first-half
1514990464_biotech_517925923.jpg
January 03 2018
Investors have been cheered by the method used to raise fresh investment, which avoids the need to issue more shares for cash
Copyright © personabelovo.ru, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated.